About
About VarmX
Our team
Portfolio
News & Events
Contact
News & events
News & events
Filter by:
All
Conferences & Events
News
Scientific publications
All
10.09.2024
Management TeamNews
VarmX announces appointment of Martijn Negen as COO
Read more
25.05.2023
News
VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it...
Read more
10.09.2024
Management TeamNews
VarmX announces appointment of Martijn Negen as COO
Read more
26.06.2024
Conferences & Events
VarmX Presents New Data at ISTH 2024
Read more
28.03.2024
Conferences & Events
VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces...
Read more
24.06.2023
Scientific publications
Coagulation assays for assessing direct FXa inhibitor oral anticoagulant reversal effect
Read more
22.06.2023
Conferences & Events
VarmX to Present Two Abstracts on Lead Compound, VMX-C001, at ISTH 2023 Congress
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces...
Read more
25.05.2023
News
VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it...
Read more
08.03.2023
News
VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the...
Read more
31.01.2023
News
VarmX appoints Paul Roos as Chief Financial Officer
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the...
Read more
09.07.2022
Scientific publications
Preclinical safety and toxicokinetics of VMX-C001 – an intravenous bypassing agent for factor Xa inhibitors
Read more
Page
1
Page
2
Page
3
VMX-C001:
Transforming the treatment of bleeding in patients taking Factor Xa DOACs
Portfolio